SAFETYLIT WEEKLY UPDATE

We compile citations and summaries of about 400 new articles every week.
RSS Feed

HELP: Tutorials | FAQ
CONTACT US: Contact info

Search Results

Journal Article

Citation

Burger DM, de Mast Q, Schellekens AF. Ned. Tijdschr. Geneeskd. 2015; 159: A8357.

Vernacular Title

Efavirenz en risico op zelfmoord bij hiv-patiƫnten.

Affiliation

Radboudumc, Nijmegen.

Copyright

(Copyright © 2015, Erven Bohn)

DOI

unavailable

PMID

25650033

Abstract

Efavirenz is widely used as part of combination antiretroviral therapy in HIV-infected patients. Central nervous system adverse effects are the most important reason for discontinuation of this drug. A recent combined analysis of phase III data showed a two-fold increased risk of suicidal ideation or suicide attempts, when compared with non-efavirenz-containing regimens. This commentary discusses the data from this analysis, tries to explain these observations and the implications for clinical practice, and puts them into perspective in relation to efavirenz's prominent position as a first-line drug for the treatment of HIV infection.


Language: nl

NEW SEARCH


All SafetyLit records are available for automatic download to Zotero & Mendeley
Print